http://www.reuters.com/article/us-valeant-ceo-idUSKCN0YE1LT
Papa told investors at the UBS Global Healthcare Conference that the company would fund the payoffs in part through the sale of non-core assets outside of its main franchises if it can get attractive prices for the assets.
Papa said core assets include the dermatology business, Bausch & Lomb eyecare, and its gastroenterology products, many of which were acquired in its purchase of Salix Pharmaceuticals last year.
...No mention of ECR being a core asset folks. We have six months max.
